Related Experiment Video
Updated: Apr 25, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Atypical polycystic ovary syndrome--a genetic analysis
M Scholten1, C Vilser1, A Weise2
1Department of Pediatrics, Jena University Hospital, Jena, Germany.
Polycystic ovary syndrome (PCOS) may involve atypical androgen receptor (AR) signaling due to mutations affecting codon usage. Further research into AR-coregulators and epigenetic factors is warranted for understanding PCOS pathogenesis.
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Polycystic ovary syndrome (PCOS) is a common endocrine disorder with incompletely understood pathogenesis.
- High androgen levels typically correlate with increased virilization in PCOS.
- Atypical presentations include high testosterone with low virilization, or low testosterone with high virilization.
Observation:
- This study investigated 6 patients with atypical PCOS presentations.
- Methods included chromosomal analysis (GTG staining) and sequencing of the androgen receptor (AR) gene, including CAG and GGC repeat lengths.
- No chromosomal alterations or variations in repeat lengths were found.
Findings:
- Sequencing identified genetic mutations in the AR gene.
- These mutations do not alter the AR protein sequence but affect codon usage.
- Altered codon usage may impact AR protein levels and androgen signaling.
Implications:
- This is the first study to combine chromosomal analysis with full AR gene sequencing in PCOS patients.
- Findings suggest that altered codon usage in the AR gene may contribute to atypical PCOS.
- Other potential factors include AR-coregulators and epigenetic alterations, requiring further investigation.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Oogenesis
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Karyotyping
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

